Zurich Cantonal Bank’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Zurich Cantonal Bank’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$232K	Sell	1,468 -2,441	-62%	-$330K	﹤0.01%	2275
2026 Q1	$465K	Buy	+3,909	New	+$488K	﹤0.01%	1867
2025 Q4	–	Sell	-4,486	Closed	-$514K	–	3437
2025 Q3	$446K	Hold	4,486	–	–	﹤0.01%	1811
2025 Q2	$372K	Sell	4,486 -90	-2%	-$7.18K	﹤0.01%	1842
2025 Q1	$386K	Sell	4,576 -19,021	-81%	-$1.7M	﹤0.01%	1753
2024 Q4	$2.12M	Sell	23,597 -276	-1%	-$26.7K	0.01%	823
2024 Q3	$2.37M	Buy	23,873 +148	+0.6%	+$14.5K	0.01%	752
2024 Q2	$2.19M	Sell	23,725 -1,532	-6%	-$137K	0.01%	735
2024 Q1	$2.4M	Buy	+25,257	New	+$2.34M	0.01%	706
2023 Q3	–	Sell	-987	Closed	-$81.5K	–	2801
2023 Q2	$81.5K	Sell	987 -9,373	-90%	-$784K	﹤0.01%	2434
2023 Q1	$774K	Buy	10,360 +235	+2%	+$19.5K	﹤0.01%	1027
2022 Q4	$833K	Sell	10,125 -129	-1%	-$10.4K	﹤0.01%	960
2022 Q3	$808K	Buy	10,254 +176	+2%	+$14.8K	﹤0.01%	922
2022 Q2	$754K	Sell	10,078 -14,297	-59%	-$1.07M	﹤0.01%	982
2022 Q1	$2.21M	Buy	24,375 +326	+1%	+$30.1K	0.01%	700
2021 Q4	$2.73M	Buy	24,049 +764	+3%	+$92.1K	0.01%	670
2021 Q3	$2.92M	Buy	23,285 +273	+1%	+$35.2K	0.02%	660
2021 Q2	$3.12M	Buy	23,012 +38	+0.2%	+$5K	0.02%	614
2021 Q1	$2.99M	Buy	22,974 +1,137	+5%	+$170K	0.02%	609
2020 Q4	$3.15M	Buy	21,837 +2,399	+12%	+$307K	0.02%	616
2020 Q3	$2.17M	Buy	19,438 +659	+4%	+$73.9K	0.02%	674
2020 Q2	$2.07M	Buy	18,779 +1,814	+11%	+$179K	0.02%	635
2020 Q1	$1.33M	Buy	16,965 +8,230	+94%	+$729K	0.01%	682
2019 Q4	$827K	Buy	8,735 +200	+2%	+$17.3K	0.01%	842
2019 Q3	$652K	Hold	8,535	–	–	0.01%	859
2019 Q2	$749K	Buy	8,535 +1,900	+29%	+$162K	0.01%	854
2019 Q1	$601K	Buy	6,635 +900	+16%	+$76.6K	0.01%	852
2018 Q4	$411K	Buy	5,735 +700	+14%	+$56.4K	﹤0.01%	931
2018 Q3	$483K	Buy	5,035 +635	+14%	+$61.6K	﹤0.01%	938
2018 Q2	$419K	Hold	4,400	–	–	﹤0.01%	946
2018 Q1	$386K	Buy	+4,400	New	+$402K	﹤0.01%	925

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Zurich Cantonal Bank's XBI Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 62% in Q2 2026, selling an estimated $330K and leaving 1,468 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #2275.

Zurich Cantonal Bank first reported a position in XBI in Q1 2018 and has held it in 31 quarters since. The position peaked at $3.15M in Q4 2020. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Zurich Cantonal Bank held 1,468 shares of State Street SPDR S&P Biotech ETF worth $232K as of Q2 2026.
Zurich Cantonal Bank sold 2,441 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $330K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2275 holding.
Zurich Cantonal Bank first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 31 quarters since.
Zurich Cantonal Bank's State Street SPDR S&P Biotech ETF position peaked at $3.15M in Q4 2020.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.